Tepotinib

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Tepotinib Hepatic Impairment Trial

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

The Drug Rediscovery Protocol (DRUP Trial)

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Effect of Tepotinib on PK of CYP3A Substrate Midazolam

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

c-Met Second-Line Hepatocellular Carcinoma